Ask AI

APPlexus Hot Topics 2025

Stream on-demand webcasts with accompanying downloadable slides and read expert-written ClinicalThought commentaries from APPlexus Hot Topics 2025, designed and tailored specifically for advanced practice providers. Learn about the latest updates in the management of breast cancer with CDK4/6 inhibitors and antibody–drug conjugates and new strategies using targeted therapies for CLL/SLL and bispecific antibodies for DLBCL and for managing adverse events associated with BTK inhibitor therapy in patients with lymphoma.

Share

Program Content

Events

Live Event APPlexus Fall 2025: Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer
APPlexus Fall 2025: Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer
Congratulations: You achieved a completion on 04/09/2022

You can enroll in the following live event(s) on this topic.

Activities

ADCs in Breast Cancer
Maximizing Efficacy and Minimizing Toxicities With Antibody–Drug Conjugates in Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2025

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC.

Supporters

The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Supported by an educational grant from Lilly.

Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Supported by an educational grant from Lilly.

Maximizing Efficacy and Minimizing Toxicities With Antibody–Drug Conjugates in Breast Cancer

Supported by an educational grant from Gilead Sciences, Inc.

The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Supported by an educational grant from BeOne Medicines.

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Supported by an educational grant from Genmab US, Inc.

BeOne Medicines

Genmab US, Inc.

Gilead Sciences, Inc.

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner